Q-omics provides the consensus-scored SPTA1 profile across patient tissues and cancer cell-line models. SPTA1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPTA1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SPTA1 protein abundance shows 15,167 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRP, KIRC, and CCRCC as cancer lineages where SPTA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTA1 survival associations across molecular data types. SPTA1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (13) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTA1 RNA expression–survival associations across cancer types. High SPTA1 expression shows unfavorable associations in KIRP, BLCA, LUSC and ACC, but favorable associations in PCPG and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPTA1 RNA expression.
This table summarizes SPTA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPTA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTA1 shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, STAD, LIHC and HNSC. The KIRC box plot shows higher SPTA1 RNA expression in tumor versus normal tissue (log2 FC = +0.137, t-test p < 0.001).
This table shows molecular features associated with SPTA1 in patient tissues and cancer cell lines. In patient samples, SPTA1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
